Allo-SCT for AML and MDS with treosulfan compared with BU-based regimens: reduced toxicity vs reduced intensity (Q83427652)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22327135%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

title

Allo-SCT for AML and MDS with treosulfan compared with BU-based regimens: reduced toxicity vs reduced intensity (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22327135%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

author name string

A Shimoni

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22327135%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

N Shem-Tov

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22327135%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

Y Volchek

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22327135%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

I Danylesko

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22327135%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

R Yerushalmi

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22327135%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

A Nagler

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22327135%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

publication date

13 February 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22327135%20AND%20SRC:MED&resulttype=core&format=json

Bone Marrow Transplantation

22 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22327135%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

volume

47

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22327135%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22327135%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

page(s)

1274-1282

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22327135%20AND%20SRC:MED&resulttype=core&format=json

Optimizing the conditioning regimen for allogeneic stem-cell transplantation in acute myeloid leukemia; dose intensity is still in need

22 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.4

7 January 2021

Defining the intensity of conditioning regimens: working definitions

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.4

7 January 2021

Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.4

7 January 2021

Cytotoxic effects of treosulfan and busulfan against leukemic cells of pediatric patients

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.4

7 January 2021

Myeloablative and immunosuppressive properties of treosulfan in mice

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.4

7 January 2021

Treosulfan-based conditioning before hematopoietic SCT: more than a BU look-alike

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.4

7 January 2021

Fludarabine and treosulfan: a novel modified myeloablative regimen for allogeneic hematopoietic stem-cell transplantation with effective antileukemia activity in patients with acute myeloid leukemia and myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.4

7 January 2021

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.4

7 January 2021

Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.4

7 January 2021

National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.4

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.4

7 January 2021

Estimation of failure probabilities in the presence of competing risks: new representations of old estimators

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.4

7 January 2021

Allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies after dose-escalated treosulfan/fludarabine conditioning.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.4

7 January 2021

Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective s

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.4

7 January 2021

Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.4

7 January 2021

Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.4

7 January 2021

Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.4

7 January 2021

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.4

7 January 2021

Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS).

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.4

7 January 2021

Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.4

7 January 2021

Comparison between two fludarabine-based reduced-intensity conditioning regimens before allogeneic hematopoietic stem-cell transplantation: fludarabine/melphalan is associated with higher incidence of acute graft-versus-host disease and non-relapse

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.4

7 January 2021

Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.4

7 January 2021

Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.4

7 January 2021

Myeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.4

7 January 2021

Reduced-toxicity conditioning with treosulfan and fludarabine in allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes: final results of an international prospective phase II trial.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.4

7 January 2021

Ablative allogeneic hematopoietic cell transplantation in adults 60 years of age and older

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.4

7 January 2021